Saturday - December 13, 2025
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
December 06, 2025
BOSTON, Massachusetts, Dec. 6 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)

*

Pivotal phase III VERONA trial results presented at the American Society of Hematology annual meeting show no overall survival improvement, but potential for sub-group benefit and no added side effects.
. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products